Cargando…

Choosing a Second Biologic Agent for Inflammatory Bowel Disease Patients—Cost Considerations and Clinical Outcomes

Detalles Bibliográficos
Autor principal:	Clarke, Kofi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802441/ https://www.ncbi.nlm.nih.gov/pubmed/36777295 http://dx.doi.org/10.1093/crocol/otaa032

Ejemplares similares

Addressing Fecal Incontinence in Inflammatory Bowel Disease Patients: A Messy Problem
por: Clarke, Kofi
Publicado: (2021)

Addressing Sexual Dysfunction in Patients with Inflammatory Bowel Disease—We Can Do Better
por: Clarke, Kofi
Publicado: (2020)

Targeted Tuberculosis Surveillance Testing in Patients With Inflammatory Bowel Disease: Is That the Best Way Forward?
por: Clarke, Kofi
Publicado: (2021)

Which biologic agents increase perioperative complications in patients with inflammatory bowel disease?
por: Park, Jihye
Publicado: (2022)

How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease
por: Laredo, Viviana, et al.
Publicado: (2022)

Access to High-Cost Biological Agents: Perceptions of Brazilian Patients with Inflammatory Bowel Diseases
por: Parra, Rogerio Serafim, et al.
Publicado: (2023)

Trends in Healthcare Costs for Inflammatory Bowel Disease in South Korea
por: Jung, Yoon Suk
Publicado: (2020)

All Systems Go: Reconsidering Healthcare Costs in Inflammatory Bowel Disease
por: Stein, Daniel J.
Publicado: (2020)

Oral Health in Patients with Inflammatory Bowel Diseases Qualified for Biologic Treatment
por: Nijakowski, Kacper
Publicado: (2022)

Considerations for the Use of Biologic Agents in Patients With Chronic Rhinosinusitis With Nasal Polyposis
por: Kim, Do Hyun, et al.
Publicado: (2021)

Consideration of load distribution and native soft tissue anatomy when choosing an animal bony model
por: Anastasio, Albert T., et al.
Publicado: (2023)

Reproductive Biology and Endocrinology – Choose an exciting venture for the scientific future
por: Bukovsky, Antonin
Publicado: (2003)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Inflammatory Bowel Disease
por: Sachar, David B., et al.
Publicado: (2012)

Inflammatory bowel disease: Clinical screening and transition of care
por: Al-Bawardy, Badr
Publicado: (2017)

Clinical and Technical Considerations of Luting Agents for Fixed Prosthodontics
por: Pameijer, Cornelis H., et al.
Publicado: (2012)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
por: Ahn, Soo Min, et al.
Publicado: (2023)

Biologic agents in inflammatory bowel disease – quality of internet website information
por: Rofaiel, Rymon, et al.
Publicado: (2018)

Considerations on the Calculation of the Human Equivalent Dose from Toxicology Studies for Biologic Anticancer Agents
por: Elmeliegy, Mohamed, et al.
Publicado: (2021)

Variations in the medical treatment of inflammatory bowel disease among gastroenterologists
por: Singh, Shailendra, et al.
Publicado: (2018)

Why Is There Low Utilization of Biosimilars in Inflammatory Bowel Disease Patients by Gastroenterology Advanced Practice Providers?
por: Bernasko, Nana, et al.
Publicado: (2021)

Costs in inflammatory bowel diseases
por: Petryszyn, Paweł W., et al.
Publicado: (2016)

Bowel Preparation in Inflammatory Bowel Disease—A Necessary Evil?
por: Lightner, Amy L
Publicado: (2020)

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
por: Hakizimana, Ali, et al.
Publicado: (2017)

Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic
por: Iborra, Ignacio, et al.
Publicado: (2021)

Gastrointestinal hypoalgesia in inflammatory bowel disease
por: Coates, Matthew D., et al.
Publicado: (2020)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Choosing Wisely Statins
Publicado: (2020)

Pharmacogenetics of Biological Agents Used in Inflammatory Bowel Disease: A Systematic Review
por: Lauro, Rita, et al.
Publicado: (2021)

Various Forms of Tuberculosis in Patients with Inflammatory Bowel Diseases Treated with Biological Agents
por: Krusiński, Adam, et al.
Publicado: (2021)

Disability Index as a New Outcome Measure in Patients with Inflammatory Bowel Disease
por: Choi, Hyun Ho, et al.
Publicado: (2017)

Hygiene hypothesis in inflammatory bowel disease
por: Saidel-Odes, Lisa, et al.
Publicado: (2014)

Targeting lymphatics in inflammatory bowel disease
por: D'Aiessio, Silvia, et al.
Publicado: (2015)

Novel Topics in Inflammatory Bowel Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2016)

Extraintestinal Manifestations of Inflammatory Bowel Disease
por: Al-Quorain, Abdulaziz A.
Publicado: (2019)

The great wall of inflammatory bowel disease
por: Al Sulais, Eman, et al.
Publicado: (2022)

Inflammatory Bowel Disease: A Global Disease
por: Ghosh, Subrata, et al.
Publicado: (2013)

Practical considerations for choosing a mouse model of Alzheimer’s disease
por: Jankowsky, Joanna L., et al.
Publicado: (2017)

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
por: Dahmus, Jessica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ek184eopf63e3883hjojmkmta4